Ekso Bionics announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,967,742 shares of common stock at a purchase price of $1.55 per share pursuant to a registered direct offering, resulting in total gross proceeds of approximately $4.6M before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about January 16, subject to the satisfaction of customary closing conditions. The company intends to use the net proceeds from the offering for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EKSO:
- Ekso Bionics Launches GaitCoach Software for EksoNR
- Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results
- Ekso Bionics receives CMS coding approval for Ekso Indego Personal
- Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29